TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20230185

Group type: EXPERIMENTAL
Intervention: Steroid-free regimen (Tacrolimus, Mycophenolate mofetil, Basiliximab induction, steroids for 3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Steroid maintenance regimen (Tacrolimus, Mycophenolate mofetil, Basiliximab induction, steroid maintenance)
Number of subjects: 100
Study: 18056435

Group type: EXPERIMENTAL
Intervention: High cysteinylglycine levels in the vitamin E placebo group
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: High cysteinylglycine levels in the high alcohol intake group (>or=9 g/day)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: High cysteinylglycine levels in the overweight and obese group
Number of subjects: 812
Study: 16321271

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 59

Group type: COMPARATOR
Intervention: Human soluble insulin
Number of subjects: 59
Study: 12177729

Group type: EXPERIMENTAL
Intervention: Bone-free lean body mass (BF-LBM)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bone mineral content (BMC)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Fat mass (FM)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sex, age, height, and BF-LBM*Height
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Prediction equations based on sex, age, height, and BF-LBM*Height
Number of subjects: 118
Study: 10025442

Group type: EXPERIMENTAL
Intervention: 85.8 g amino acid mixture lacking tryptophan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Balanced amino acid mixture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls (12 subjects)
Number of subjects: 10
Study: 8535321

Group type: EXPERIMENTAL
Intervention: ABMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 0
Study: 2311219

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation during repletion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6138551

Group type: EXPERIMENTAL
Intervention: Lambswool bedding
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cotton sheets (control)
Number of subjects: 34
Study: 31308304

Group type: EXPERIMENTAL
Intervention: Once-daily insulin degludec/insulin aspart (IDegAsp), n = 26
Number of subjects: 52

Group type: COMPARATOR
Intervention: Once-daily basal insulin (insulin degludec and insulin glargine 300 units/mL), n = 26
Number of subjects: 52
Study: 27801991

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (b-MI)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 316
Study: 25679398

Group type: EXPERIMENTAL
Intervention: Darbepoietin‐α treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Training-ESA group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary-placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary-ESA
Number of subjects: 36

Group type: COMPARATOR
Intervention: Training-placebo
Number of subjects: 36
Study: 23594239

Group type: EXPERIMENTAL
Intervention: Daily dose of 325 mg of aspirin (ASA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 24
Study: 21394642

Group type: EXPERIMENTAL
Intervention: Bradykinin (B(2) agonist)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 11

Group type: COMPARATOR
Intervention: Lys‐des‐Arg(9)‐bradykinin (B(1) agonist)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bradykinin with angiotensin‐converting enzyme inhibition
Number of subjects: 11
Study: 19714604

Group type: EXPERIMENTAL
Intervention: Belimumab (1, 4, or 10 mg/kg)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 449
Study: 20519906

Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion
Number of subjects: 64

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 64
Study: 16298691

Group type: EXPERIMENTAL
Intervention: Nondiabetic patients with a history of severe chest pain attacks
Number of subjects: 568

Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 568
Study: 12040135

Group type: EXPERIMENTAL
Intervention: Early interventive social service program
Number of subjects: 105
Study: 9784084

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day for 6 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7929869

Group type: EXPERIMENTAL
Intervention: CL 275,838 (50 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CL 275,838 (100 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3361785

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal (N2O/O2) anesthesia
Number of subjects: 14
Study: 30591703

Group type: EXPERIMENTAL
Intervention: C₁‐L protocol group (n=293)
Number of subjects: 408

Group type: COMPARATOR
Intervention: OC‐L protocol group (n=91)
Number of subjects: 408

Group type: COMPARATOR
Intervention: GnRH antagonist protocol group (n=80)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 408
Study: 27152422

Group type: EXPERIMENTAL
Intervention: 8 mg of IV dexamethasone before general anesthesia, BIS 35-45
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 8 mg of IV dexamethasone before general anesthesia, BIS 46-55
Number of subjects: 140

Group type: COMPARATOR
Intervention: No dexamethasone, BIS 35-45
Number of subjects: 140

Group type: COMPARATOR
Intervention: No dexamethasone, BIS 46-55
Number of subjects: 140
Study: 24717957

Group type: EXPERIMENTAL
Intervention: Electrolyzed acid water (EAW) nasal irrigation daily for 2 months
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Neutral normal saline (NS) nasal irrigation daily for 2 months
Number of subjects: 185

Group type: COMPARATOR
Intervention: No nasal irrigation after surgery
Number of subjects: 185
Study: 21996342

Group type: EXPERIMENTAL
Intervention: High-dose allergen patches
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 132
Study: 20469958

Group type: EXPERIMENTAL
Intervention: Telephonic counseling program utilizing a predictive model
Number of subjects: 43497

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 43497
Study: 18310048

Group type: EXPERIMENTAL
Intervention: Follicular cells from pregnant patients
Number of subjects: 40
Study: 15892409

Group type: EXPERIMENTAL
Intervention: Combination of i.v. lidocaine and nitrous oxide in oxygen inhalation
Number of subjects: 102

Group type: COMPARATOR
Intervention: i.v. lidocaine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen inhalation
Number of subjects: 102
Study: 12883063

Group type: EXPERIMENTAL
Intervention: Intervention leaflet containing additional information on risks and uncertainties
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group based on an NHS Cervical Screening Programme leaflet
Number of subjects: 300
Study: 10565453

Group type: EXPERIMENTAL
Intervention: Urinary bile alcohols in infants with mild to severe cholestasis
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Urinary bile alcohols in infants with slight cholestasis
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Comparison of urinary bile alcohol spectrum in infants vs adults
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Detection of bile alcohols carrying chenodeoxycholic acid type nucleus
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Identification of 5beta-cholestane-3alpha,7alpha,24,25-tetrol
Number of subjects: 6
Study: 8941648

Group type: EXPERIMENTAL
Intervention: GBS type III CPS‐tetanus toxoid conjugate (III‐TT) vaccine (highest dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unconjugated GBS type III CPS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study: 2021794

Group type: EXPERIMENTAL
Intervention: Novo radioisotope based dual photon densitometer
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lunar X-ray densitometer
Number of subjects: 94
Study: 6313595

Group type: EXPERIMENTAL
Intervention: Oral acyclovir 200 mg every 6 hours from day 8 to day 35 after transplantation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 39
Study: 31022980

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioural control group
Number of subjects: 0
Study: 29308944

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test or colonoscopy (specific intervention details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: N/A (non-participants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N/A (participants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N/A (both groups)
Number of subjects: 0
Study: 27333284

Group type: EXPERIMENTAL
Intervention: ivabradine 2.5, 5, or 7.5 mg b.i.d. for 4 months
Number of subjects: 8555
Study: 25181937

Group type: EXPERIMENTAL
Intervention: Supervised group exercise program
Number of subjects: 203
Study: 22606977

Group type: EXPERIMENTAL
Intervention: Peer support intervention (biweekly visits for 2 months, then weekly)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard care (adherence counselling, monthly health check, drug refills)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 228
Study: 20958200

Group type: EXPERIMENTAL
Intervention: Web-based self-administered questionnaire (Web SAQ)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Paper-and-pencil self-administered questionnaire
Number of subjects: 190
Study: 17066232

Group type: EXPERIMENTAL
Intervention: Intra-arterial adjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intra-arterial adjuvant chemotherapy
Number of subjects: 22
Study: 15750369

Group type: EXPERIMENTAL
Intervention: Active treatment (flexion‐distraction chiropractic manipulation and trigger point therapy)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control treatment (sham manipulation and effleurage)
Number of subjects: 111
Study: 11493843

Group type: EXPERIMENTAL
Intervention: Safe lifting arm (intensive training in back care, patient assessment, and handling techniques with improved patient handling techniques using manual equipment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No strenuous lifting arm (intensive training in back care, patient assessment, and handling techniques with additional mechanical and other assistive equipment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 0
Study: 9716141

Group type: EXPERIMENTAL
Intervention: Heterozygosity for the factor V (Arg506-->Gln) mutation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-carriers of the factor V (Arg506-->Gln) mutation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative APC ratios
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative prothrombin fragment 1+2, thrombin-antithrombin complexes and soluble fibrin levels
Number of subjects: 108
Study: 7981088

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 237
Study: 2541975

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4097650

Group type: EXPERIMENTAL
Intervention: Combined preparation of triiodothyronine and thyroxine (1:4 ratio)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Thyroxine alone
Number of subjects: 87
Study: 31746623

Group type: EXPERIMENTAL
Intervention: Standardized interview (WHO/PAHO) for diagnosing night blindness (NB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroretinography for diagnosing night blindness (NB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum concentrations of retinol
Number of subjects: 0
Study: 30861580

Group type: EXPERIMENTAL
Intervention: Galcanezumab (120 mg and 240 mg)
Number of subjects: 2850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2850
Study: 28113032

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg once per day for 5 years)
Number of subjects: 4136

Group type: COMPARATOR
Intervention: Anastrozole (1 mg once per day for 5 years)
Number of subjects: 4136

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4136
Study: 25641570

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIg) + lamivudine (LAM) followed by long-term prophylaxis with LAM
Number of subjects: 29

Group type: COMPARATOR
Intervention: Long-term prophylaxis with LAM without HBIg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both prophylactic strategies (HBIg + LAM and LAM alone)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ultra-deep pyrosequencing (UDPS) analysis
Number of subjects: 29
Study: 23279614

Group type: EXPERIMENTAL
Intervention: Once-daily extended-release tacrolimus (LCPT)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Tacrolimus twice daily (control)
Number of subjects: 326
Study: 21063726

Group type: EXPERIMENTAL
Intervention: High-intensity vibration (HLV, f = 300 Hz)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Resistance training program (cR group, n = 18)
Number of subjects: 18
Study: 19930092

Group type: EXPERIMENTAL
Intervention: Individually tailored oral health educational programme
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 113
Study: 17250932

Group type: EXPERIMENTAL
Intervention: Zoster vaccine (approximately 50,000 PFU)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15489368

Group type: EXPERIMENTAL
Intervention: Plasma light (2 seconds)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High intensity quartz halogen light (10 seconds)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Standard quartz halogen light (20 seconds)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Plasma light (4 seconds)
Number of subjects: 9
Study: 10665552

Group type: COMPARATOR
Intervention: Aspirin (80 mg orally twice daily)
Number of subjects: 9233

Group type: EXPERIMENTAL
Intervention: Low-dose sibrafiban (3.0 mg, 4.5 mg, or 6.0 mg)
Number of subjects: 9233

Group type: EXPERIMENTAL
Intervention: High-dose sibrafiban (3.0 mg, 4.5 mg, or 6.0 mg)
Number of subjects: 9233

Group type: EXPERIMENTAL
Intervention: High-dose sibrafiban
Number of subjects: 9233

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 9233

Group type: EXPERIMENTAL
Intervention: Low-dose sibrafiban
Number of subjects: 9233
Study: 9374092

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 as a 1-hour infusion followed by paclitaxel 200 mg/m2 as a 3-hour infusion every 3 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 plus paclitaxel 200 mg/m2
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Epirubicin plus paclitaxel
Number of subjects: 35
Study: 1288930

Group type: EXPERIMENTAL
Intervention: Acupuncture on Zusanli points (ST36)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 80
Study: 3884881

Group type: EXPERIMENTAL
Intervention: 24-hour creatinine clearance (24-hr CCr) in transplant patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: 24-hour creatinine clearance (24-hr CCr) in healthy women
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mean 24-hr CCr in late pregnancy in transplant patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mean 24-hr CCr in late pregnancy in healthy women
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protein excretion in transplant patients during pregnancy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Protein excretion in healthy women during pregnancy
Number of subjects: 10
Study: 31330524

Group type: EXPERIMENTAL
Intervention: Universal screening of children for FH
Number of subjects: 30
Study: 29880276

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carotid artery (c) vs Facial artery (f)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carotid artery (c) vs Metatarsal artery (m)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cardiac output (Q˙t) and systemic vascular resistance (SVR)
Number of subjects: 8
Study: 27932335

Group type: EXPERIMENTAL
Intervention: 2.5 mg apixaban, administered twice daily for 3 years as adjunct therapy to stable oral PAH therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 3 years as adjunct therapy to stable oral PAH therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 mg apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 0
Study: 24431447

Group type: EXPERIMENTAL
Intervention: Threshold-contrast detection task
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-contrast speed discrimination task
Number of subjects: 0
Study: 22612884

Group type: EXPERIMENTAL
Intervention: Music with headphones
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Headphones only
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study: 19309726

Group type: EXPERIMENTAL
Intervention: Citalopram (16 week RCT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No depression (Control group)
Number of subjects: 34
Study: 17868539

Group type: EXPERIMENTAL
Intervention: Total dose 4.5 g of azithromycin in 7 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total dose 6.0 g of azithromycin in 10 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total dose 7.5 g of azithromycin in 13 weeks
Number of subjects: 120
Study: 15167314

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐estradiol + 0.125 mg trimegestone (n = 179)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo (n = 181)
Number of subjects: 360
Study: 12851621

Group type: EXPERIMENTAL
Intervention: Delapril plus isosorbide-5-mononitrate (IS5MN)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Delapril plus IS5MN
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Lisinopril plus isosorbide-5-mononitrate (IS5MN)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Lisinopril plus IS5MN
Number of subjects: 177
Study: 10579117

Group type: EXPERIMENTAL
Intervention: PiZ carriers
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: BPI-ANCA
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: PR3-ANCA
Number of subjects: 141
Study: 8562413

Group type: EXPERIMENTAL
Intervention: Serum eNCAM levels in patients with multiple myeloma
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Serum eNCAM levels in patients with high tumour burdens
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Correlation of serum eNCAM with beta 2-microglobulin
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Survival of patients with low serum eNCAM
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Serum eNCAM as a prognostic factor
Number of subjects: 92
Study: 1906258

Group type: EXPERIMENTAL
Intervention: Cefaclor (20 to 40 mg/kg/day in three divided doses for 10 days)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Penicillin V (50,000 to 100,000 IU/kg/day in three divided doses for 10 days)
Number of subjects: 117
Study: 6315646

Group type: EXPERIMENTAL
Intervention: Ordinary wheat bran (20 grams added to diet)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-phytate wheat bran (20 grams added to diet)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hospital diet (control group)
Number of subjects: 10
Study: 3861184

Group type: EXPERIMENTAL
Intervention: Conventional low-fat diet (carbohydrate 56%; fat 25%; vegetable proteins 7%; animal proteins 12% of energy; P/S ratio 1.0)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Different low-fat diet (69% of energy as carbohydrate, 19% as fat, 7% as vegetable proteins and 5% as animal proteins; P/S ratio 1.3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both diets (cross-over study on 24 patients)
Number of subjects: 32
Study: 31350768

Group type: EXPERIMENTAL
Intervention: BDF + Ib (manual brushing/dental flossing + interdental brushes)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: BDF + Oi (manual brushing/dental flossing + oral irrigator)
Number of subjects: 142

Group type: COMPARATOR
Intervention: BDF (manual brushing/dental flossing only)
Number of subjects: 142
Study: 28855344

Group type: EXPERIMENTAL
Intervention: iSMI (internet-based stress management intervention)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 117
Study: 27505335

Group type: EXPERIMENTAL
Intervention: Intensive atorvastatin (40mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard atorvastatin (20mg)
Number of subjects: 120
Study: 26414124

Group type: EXPERIMENTAL
Intervention: Cigarette smokers with high pack-year exposure
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Cigarette smokers with low pack-year exposure
Number of subjects: 127

Group type: COMPARATOR
Intervention: Young onset/atopic cluster
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nonsmoker/less eosinophilic cluster
Number of subjects: 127

Group type: COMPARATOR
Intervention: Female/obese cluster
Number of subjects: 127
Study: 23402967

Group type: EXPERIMENTAL
Intervention: 10/100 method (10-s break after 100 compressions)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 10/200 method (10-s break after 200 compressions)
Number of subjects: 63

Group type: COMPARATOR
Intervention: CCC method (continuous chest compression without a break)
Number of subjects: 63
Study: 20571306

Group type: EXPERIMENTAL
Intervention: Carnitine complex
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 18948811

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 50
Study: 16832679

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg orally twice daily for 3 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10